Opus Genetics (IRD) Amortizatization of Intangibles (2018 - 2020)
Opus Genetics (IRD) reported Amortizatization of Intangibles of -$1000.0 for Q4 2020, down 100.11% year-over-year from $927230.0 in Q1 2020, and down 112.5% on a QoQ basis from $8000.0 in Q3 2020.
Opus Genetics (IRD) has 3 years of Amortizatization of Intangibles data on file, last reported at -$1000.0 in Q4 2020.
- Quarterly Amortizatization of Intangibles fell 100.11% year-over-year to -$1000.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was -$1000.0 (down 100.06% YoY) and the FY2020 annual result came in at $873000.0, down 13.91% from the prior year.
- Amortizatization of Intangibles fell to -$1000.0 in Q4 2020 per IRD's latest filing, from $8000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $927230.0 in Q4 2019 and bottomed at -$14907.0 in Q1 2018.
- The 3-year median for Amortizatization of Intangibles is $13249.5 (2019), against an average of $154812.4.
- The widest annual swing landed in 2019, when Amortizatization of Intangibles soared 22491.45%; it then plunged 100.11% in 2020.
- Tracing IRD's Amortizatization of Intangibles over 3 years: stood at -$4141.0 in 2018, then jumped by 22491.45% to $927230.0 in 2019, then sank by 100.11% to -$1000.0 in 2020.
- Per Business Quant, the three latest IRD Amortizatization of Intangibles figures stand at -$1000.0 (Q4 2020), $8000.0 (Q3 2020), and $500000.0 (Q2 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -1,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 8,000.00 |
| Sep 30, 2020 | 8,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Mar 31, 2020 | 376,000.00 |
| Mar 31, 2020 | 376,000.00 |
| Dec 31, 2019 | 927,230.00 |
| Dec 31, 2019 | 927,230.00 |
| Sep 30, 2019 | 30,751.00 |
| Sep 30, 2019 | 30,751.00 |
| Jun 30, 2019 | 37,520.00 |
| Jun 30, 2019 | 37,520.00 |
| Mar 31, 2019 | 18,499.00 |
| Mar 31, 2019 | 18,499.00 |
| Dec 31, 2018 | -4,141.00 |
| Dec 31, 2018 | -4,141.00 |
| Sep 30, 2018 | -8,606.00 |
| Sep 30, 2018 | -8,606.00 |
| Jun 30, 2018 | -11,597.00 |
| Jun 30, 2018 | -11,597.00 |
| Mar 31, 2018 | -14,907.00 |
| Mar 31, 2018 | -14,907.00 |